Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Vaccines in Primary Immune Disorders
NCT00023504Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2002
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine, pneumococcal 7-valent conjugate vaccine, rabeprazole, tetanus and diphtheria toxoids vaccine in pneumococcal infection, rabies, Tetanus, diphtheria, sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2002; status: terminated.
02
Drugs
23-valent pneumococcal polysaccharide vaccinepneumococcal 7-valent conjugate vaccinerabeprazoletetanus and diphtheria toxoids vaccine
03
Conditions
pneumococcal infectionrabiesTetanusdiphtheria
Beyond the preview
Go deeper on NCT00023504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023504.